| Search Results |
Amphibian toxicity testing for identification of thyroid disrupting chemicals., Dang Z., Environ Pollut. October 15, 2022; 311 120006.
|
An amphibian high fat diet model confirms that endocrine disruptors can induce a metabolic syndrome in wild green frogs (Pelophylax spp. complex)., Veyrenc S, Regnault C, Sroda S, Raveton M, Reynaud S., Environ Pollut. October 15, 2022; 311 120009.
|
Amphibian Metamorphosis Assay: Investigation of the potential effects of five chemicals on the hypothalamic-pituitary thyroid axis of Xenopus laevis., Kamel A, Matten SR, Lynn SG, Wolf JC, Fort DJ., Regul Toxicol Pharmacol. October 1, 2022; 134 105241.
|
ANT1 overexpression models: Some similarities with facioscapulohumeral muscular dystrophy., Arbogast S, Kotzur H, Frank C, Compagnone N, Sutra T, Pillard F, Pietri S, Hmada N, Moussa DMA, Bride J, Françonnet S, Mercier J, Cristol JP, Dabauvalle MC, Laoudj-Chenivesse D., Redox Biol. October 1, 2022; 56 102450.
|
Arterial Blood Pressure, Neuronal Excitability, Mineral Metabolism and Cell Volume Regulation Mechanisms Revealed by Xenopus laevis oocytes., Gamba G., Membranes (Basel). September 21, 2022; 12 (10):
|
A genomics revolution in amphibian taxonomy., Dufresnes C, Jablonski D., Science. September 16, 2022; 377 (6612): 1272.
|
An in vivo study of the toxic effects of triclosan on Xenopus laevis (Daudin, 1802) frog: Assessment of viability, tissue damage and mitochondrial dysfunction., Tenkov KS, Dubinin MV, Vedernikov AA, Chelyadnikova YA, Belosludtsev KN., Comp Biochem Physiol C Toxicol Pharmacol. September 1, 2022; 259 109401.
|
A combined in silico and in vivo approach to the structure-function annotation of SPD-2 provides mechanistic insight into its functional diversity., Murph M, Singh S, Schvarzstein M., Cell Cycle. September 1, 2022; 21 (18): 1958-1979.
|
A myeloperoxidase enhancer drives myeloid cell-specific labeling in a transgenic frog line., Yamada-Kondo S, Ogawa A, Fukunaga M, Izutsu Y, Kato T, Maéno M., Dev Growth Differ. September 1, 2022; 64 (7): 362-367. 
|
A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes., Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, Sun L, Yang Q, Tang X, Yuan Y, Han J, Jiang N., Br J Pharmacol. September 1, 2022; 179 (17): 4360-4377.
|
